Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue
Total revenue	$ 4,214,441	$ 3,498,614
Operating expenses
Research and development, net	9,964,720	5,121,168
General and administrative	8,801,661	6,252,442
Sales and marketing	3,094,092	1,464,721
Transaction costs	471,522	779,048
Impairment of right-of-use asset	101,838	520,759
Impairment of intangible assets	750,596
Gain on sale of equipment	(100,000)
Total operating expenses	26,932,920	15,769,859
Operating loss	(22,718,479)	(12,271,245)
Other (expense) income
Gain on extinguishment of debt	884,970
Interest and other income, net	105,627	9,859
Interest expense	(3,399,384)	(187,549)
Foreign currency transaction (losses)/gains	(1,468,855)	2,410
Change in fair value of derivative financial instruments	517,680	67
Total other expense	(3,359,962)	(175,213)
Loss before income taxes	(26,078,441)	(12,446,458)
Provision for income taxes	132,403
Net loss	$ (26,210,844)	$ (12,446,458)
Net loss per common share - basic and diluted	$ (1.66)	$ (7.70)
Weighted average shares outstanding - basic and diluted	15,800,781	1,616,939
Net loss	$ (26,210,844)	$ (12,446,458)
Other comprehensive income (loss) - foreign currency translation	2,564,497	(4,222)
Comprehensive loss	(23,646,347)	(12,450,680)
Product sales [Member]
Revenue
Total revenue	2,704,364	2,168,179
Operating expenses
Cost of products and services	3,360,280	911,565
Laboratory services [Member]
Revenue
Total revenue	167,736	5,435
Operating expenses
Cost of products and services	488,211	720,156
Collaborations Revenue [Member]
Revenue
Total revenue	$ 1,342,341	$ 1,325,000